Nektar Therapeutics Earnings Dividend

Nektar Therapeutics’s revenue fell -25.25% since last year same period to $21.81Mn in the Q4 2025. On a quarterly growth basis, Nektar Therapeutics has generated 84.96% jump in its revenue since last 3-months.

Nektar Therapeutics’s net profit fell -596.89% since last year same period to $-36.08Mn in the Q4 2025. On a quarterly growth basis, Nektar Therapeutics has generated -1.57% fall in its net profits since last 3-months.

Nektar Therapeutics’s net profit margin fell -764.77% since last year same period to -165.45% in the Q4 2025. On a quarterly growth basis, Nektar Therapeutics has generated 45.09% jump in its net profit margins since last 3-months.

Nektar Therapeutics’s earning per share (EPS) estimates for the current quarter stand at -3.5 - a -1712.76% fall from last quarter’s estimates.

Nektar Therapeutics’s earning per share (EPS) estimates for the current year stand at -3.5.

Nektar Therapeutics’s earning per share (EPS) fell -759.87% since last year same period to -1.29 in the Q4 2025. This indicates that the Nektar Therapeutics has generated -759.87% annual rate of fall in its earning per share (EPS) in the last 4 quarters.